Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Botulinum toxin A (Primary)
- Indications Facial-wrinkles; Glabellar lines
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 19 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Sep 2016.
- 28 Jul 2015 Planned End Date changed from 1 Jun 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 19 Jun 2015 Planned End Date changed from 1 Sep 2016 to 1 Jun 2016 as per ClinicalTrial.gov record.